vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $14.9M, roughly 1.3× EVERSPIN TECHNOLOGIES INC.). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -541.1%, a 539.1% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 13.2%). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 18.2%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
AGIO vs MRAM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $14.9M |
| Net Profit | $-108.0M | $-296.0K |
| Gross Margin | 90.6% | 52.7% |
| Operating Margin | -608.9% | 29.0% |
| Net Margin | -541.1% | -2.0% |
| Revenue YoY | 86.1% | 13.2% |
| Net Profit YoY | -11.9% | — |
| EPS (diluted) | $-1.86 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $20.0M | $14.8M | ||
| Q3 25 | $12.9M | $14.1M | ||
| Q2 25 | $12.5M | $13.2M | ||
| Q1 25 | $8.7M | $13.1M | ||
| Q4 24 | $10.7M | $13.2M | ||
| Q3 24 | $9.0M | $12.1M | ||
| Q2 24 | $8.6M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $-108.0M | $1.2M | ||
| Q3 25 | $-103.4M | $54.0K | ||
| Q2 25 | $-112.0M | $-670.0K | ||
| Q1 25 | $-89.3M | $-1.2M | ||
| Q4 24 | $-96.5M | $1.2M | ||
| Q3 24 | $947.9M | $2.3M | ||
| Q2 24 | $-96.1M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 90.6% | 50.8% | ||
| Q3 25 | 87.0% | 51.3% | ||
| Q2 25 | 86.3% | 51.3% | ||
| Q1 25 | 87.6% | 51.4% | ||
| Q4 24 | 88.3% | 51.3% | ||
| Q3 24 | 91.3% | 49.2% | ||
| Q2 24 | 82.6% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | -608.9% | -7.2% | ||
| Q3 25 | -907.4% | -11.0% | ||
| Q2 25 | -1020.1% | -14.9% | ||
| Q1 25 | -1222.0% | -14.7% | ||
| Q4 24 | -1165.3% | -11.8% | ||
| Q3 24 | -1146.9% | -17.5% | ||
| Q2 24 | -1228.3% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | -541.1% | 8.1% | ||
| Q3 25 | -803.1% | 0.4% | ||
| Q2 25 | -899.4% | -5.1% | ||
| Q1 25 | -1023.3% | -8.9% | ||
| Q4 24 | -899.6% | 9.2% | ||
| Q3 24 | 10574.7% | 18.8% | ||
| Q2 24 | -1115.7% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $-1.86 | $0.05 | ||
| Q3 25 | $-1.78 | $0.00 | ||
| Q2 25 | $-1.93 | $-0.03 | ||
| Q1 25 | $-1.55 | $-0.05 | ||
| Q4 24 | $-1.44 | $0.07 | ||
| Q3 24 | $16.22 | $0.10 | ||
| Q2 24 | $-1.69 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $70.2M |
| Total Assets | $1.3B | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $89.1M | $44.5M | ||
| Q3 25 | $92.7M | $45.3M | ||
| Q2 25 | $80.9M | $45.0M | ||
| Q1 25 | $79.0M | $42.2M | ||
| Q4 24 | $76.2M | $42.1M | ||
| Q3 24 | $253.7M | $39.6M | ||
| Q2 24 | $84.5M | $36.8M |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $1.2B | $68.9M | ||
| Q3 25 | $1.3B | $65.8M | ||
| Q2 25 | $1.4B | $64.1M | ||
| Q1 25 | $1.5B | $63.0M | ||
| Q4 24 | $1.5B | $62.6M | ||
| Q3 24 | $1.6B | $59.3M | ||
| Q2 24 | $660.5M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $1.3B | $84.6M | ||
| Q3 25 | $1.4B | $80.3M | ||
| Q2 25 | $1.5B | $78.9M | ||
| Q1 25 | $1.6B | $80.2M | ||
| Q4 24 | $1.7B | $77.8M | ||
| Q3 24 | $1.8B | $72.6M | ||
| Q2 24 | $773.1M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $570.0K |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $-96.2M | $2.6M | ||
| Q3 25 | $-88.2M | $881.0K | ||
| Q2 25 | $-77.1M | $5.0M | ||
| Q1 25 | $-111.5M | $1.4M | ||
| Q4 24 | $-133.2M | $3.8M | ||
| Q3 24 | $-84.2M | $2.8M | ||
| Q2 24 | $-72.6M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-97.3M | $-975.0K | ||
| Q3 25 | $-89.7M | $543.0K | ||
| Q2 25 | $-78.0M | $3.0M | ||
| Q1 25 | $-112.3M | $527.0K | ||
| Q4 24 | $-134.1M | $2.1M | ||
| Q3 24 | $-84.6M | $2.8M | ||
| Q2 24 | $-72.7M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | -487.5% | -6.6% | ||
| Q3 25 | -696.5% | 3.9% | ||
| Q2 25 | -626.2% | 22.9% | ||
| Q1 25 | -1286.4% | 4.0% | ||
| Q4 24 | -1250.1% | 15.8% | ||
| Q3 24 | -944.2% | 22.9% | ||
| Q2 24 | -844.4% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | 24.3% | ||
| Q3 25 | 12.1% | 2.4% | ||
| Q2 25 | 7.0% | 15.1% | ||
| Q1 25 | 8.8% | 6.9% | ||
| Q4 24 | 9.0% | 13.2% | ||
| Q3 24 | 4.7% | 0.5% | ||
| Q2 24 | 1.8% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.16× | ||
| Q3 24 | -0.09× | 1.25× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
